31 citations
,
March 2017 in “Journal of The American Academy of Dermatology” This study observed various patterns of permanent alopecia in breast cancer patients treated with taxanes and adjuvant hormonal chemotherapy, hypothesizing disruptions in hair follicle cycles due to chemoinflammatory and hormonal factors.
48 citations
,
February 2017 in “Journal of Cosmetic Dermatology” This proposal reviews current knowledge and suggests actions for managing chemotherapy‐induced alopecia but reports no new clinical results, highlighting the need for evidence‐based guidelines.
38 citations
,
October 2014 in “British journal of dermatology/British journal of dermatology, Supplement” The study found that daily use of bimatoprost ophthalmic solution 0.03% for one year was effective in improving eyelash growth and patient satisfaction in both idiopathic and chemotherapy-induced hypotrichosis, with no serious drug-related adverse events reported.
110 citations
,
August 2014 in “International journal of cancer” This study found that scalp cooling significantly reduced the risk of chemotherapy-induced alopecia in breast cancer patients, while topical minoxidil and other interventions did not show significant efficacy.
52 citations
,
May 2013 in “Supportive Care in Cancer” Scalp cooling significantly reduces hair loss in chemotherapy patients.
33 citations
,
March 2013 in “Journal of Investigative Dermatology” Human hair follicle stem cells show signs of low oxygen levels, which may be important for hair growth and preventing baldness.
218 citations
,
January 2013 in “The Lancet Oncology” This review discusses the pathobiology of chemotherapy-induced alopecia and highlights challenges in managing it, reporting no new clinical results and emphasizing the need for well-designed preclinical models to develop effective treatments.
96 citations
,
January 2013 in “International Journal of Trichology” This article reviews the use of trichoscopy for diagnosing various types of alopecia and reports no new clinical results; it is suggested as a non-invasive method for diagnosis and monitoring treatment responses.
32 citations
,
April 2011 in “Journal of the American Academy of Dermatology” Erlotinib may cause scarring hair loss.
62 citations
,
February 2011 in “Expert review of dermatology” This review discusses the incidence, reversibility, and impact of chemotherapy-induced alopecia and concludes that scalp cooling is the most effective prevention method in most cases, though some questions remain.
25 citations
,
April 2010 in “Clinical and Experimental Dermatology” Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.
28 citations
,
January 2007 in “Dermatology” This article discusses the presentation of chemotherapy-induced anagen effluvium as either diffuse or patterned hair loss and reports no new clinical findings.
53 citations
,
January 2007 in “Dermatology” This study suggests that chemotherapy-induced anagen effluvium represents patterned hair loss, with most patients retaining hairlines, but patterns do not vary significantly by age, symptoms, or chemotherapy type.
97 citations
,
September 2006 in “Pharmaceutical Research” This review discusses advances in protecting against chemotherapy-induced alopecia and reports no new clinical results; calcitriol and cyclosporine A emerged as promising agents in animal models with broader efficacy across multiple chemotherapy drugs.
375 citations
,
February 2006 in “Journal of Cell Science” This article reviews the stages and regulation of the hair cycle, highlighting molecular regulators involved, but it does not present new research findings.
56 citations
,
July 2005 in “Experimental Dermatology” This study demonstrated that hair follicle-derived cells can induce hair follicle formation in an in vitro skin organ culture system using human retroauricular skin specimens.
39 citations
,
December 2001 in “JNCI: Journal of the National Cancer Institute” This study found that enhanced expression of the Sonic hedgehog gene via an adenovirus vector accelerated hair regrowth in mice with chemotherapy-induced alopecia.
24 citations
,
September 2001 in “Journal of Dermatological Science” This study found that cyclophosphamide-induced hair follicle damage in C3H mice could be remodelled into intact anagen hair follicles with topical cyclosporin A, especially in anagen IV stage follicles.
153 citations
,
January 2001 in “Science” In a neonatal rat model, this study found that topical CDK2 inhibitors reduced chemotherapy-induced hair loss in 33 to 50% of the animals, suggesting a potential strategy for preventing alopecia in cancer patients.
127 citations
,
July 1996 in “Journal of The American Academy of Dermatology” This study found that in women undergoing chemotherapy after breast surgery, topical minoxidil significantly shortened the duration of hair loss compared to a placebo without significant side effects.
11 citations
,
June 1996 in “Nutrition” Vitamin D3 may prevent hair loss from chemotherapy, but side effects and cancer cell protection are concerns.
49 citations
,
October 1994 in “Annals of Oncology” Minoxidil not effective in preventing chemotherapy-induced hair loss.
